NCT06856941 CsDCS on Functional Mobility in Parkinsons Disease
| NCT ID | NCT06856941 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidade Federal de Pernambuco |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 66 participants |
| Start Date | 2024-05-09 |
| Primary Completion | 2025-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 66 participants in total. It began in 2024-05-09 with a primary completion date of 2025-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Parkinsons disease is a progressive neurological disorder marked by a decline in the efficacy of dopaminergic synapses in the nigrostriatal pathway, causing motor disturbances. Resting tremor, bradykinesia, and muscle rigidity are the most prominent motor features. These factors result in gait impairments, including slowness and freezing. The primary treatment for the disease is medication. However, while medication does reduce motor symptoms, prolonged usage may lead to an increase of dyskinesias and a worsening of a patients clinical condition. Thus, alternative therapies, such as cerebellospinal direct current stimulation (csDCS), have gained popularity. Studies suggest that csDCS may be an effective approach to mitigate gait disorders in this patient population. Kinesiotherapy is an established therapeutic method that has been demonstrated to promote functional mobility and improve gait. To date, the combination of kinesiotherapy and csDCS has not been tested, thus the purpose of this study is to evaluate the effectiveness of this combined therapy for enhancing functional mobility in Parkinsons disease patients. The goal of this study is to assess the efficacy of blending csDCS and kinesiotherapy for improving patients functional mobility in Parkinsons disease. Two groups of volunteers will be assigned: i) actual csDCS + kinesiotherapy, and ii) sham csDCS + kinesiotherapy. The full procedure involves 10 therapy sessions conducted across two weeks.
Eligibility Criteria
Inclusion Criteria: * a clinical diagnosis of PD provided by a neurologist * regular dopaminergic drug treatment (at least three months of use) * aged 40 years or over * staging I to IV on the modified Hoehn and Yahr scale Exclusion Criteria: * other neurological disorders, postural hypotension, vestibular, musculoskeletal or visual disorders that compromise performance in the proposed tests * other osteoarticular diseases in the lower limbs that interfere with performance and locomotion * a Montreal Cognitive Assessment (MoCA) score of less than 21 points * have undergone previous surgery for PD
Contact & Investigator
Kátia Monte-Silva
STUDY DIRECTOR
Universidade Federal de Pernambuco
Frequently Asked Questions
Who can join the NCT06856941 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06856941 currently recruiting?
Yes, NCT06856941 is actively recruiting participants. Contact the research team at monte.silvakk@gmail.com for enrollment information.
Where is the NCT06856941 trial being conducted?
This trial is being conducted at Recife, Brazil.
Who is sponsoring the NCT06856941 clinical trial?
NCT06856941 is sponsored by Universidade Federal de Pernambuco. The principal investigator is Kátia Monte-Silva at Universidade Federal de Pernambuco. The trial plans to enroll 66 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.